Record 2025 results with 17% sales growth and 26% EBITA increase, driven by strong organic growth and three acquisitions. Solid financial position, robust cash flow, and continued focus on both organic and acquisition-driven expansion in the Life Science sector.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.